Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from vTv Therapeutics ( (VTVT) ) is now available.
vTv Therapeutics has updated their slide presentation to highlight their progress in developing cadisegliatin, a novel oral liver-selective glucokinase activator for Type 1 Diabetes. This development, still undergoing clinical trials and regulatory processes, aims to address the high unmet need for more effective glycemic control solutions, potentially providing investors and stakeholders with significant market opportunities.
More about vTv Therapeutics
vTv Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of oral drugs for chronic diseases. Their primary market involves treatments for diabetes, specifically targeting Type 1 Diabetes with their advanced cadisegliatin program.
YTD Price Performance: 1.68%
Average Trading Volume: 30,901
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $44.02M
For an in-depth examination of VTVT stock, go to TipRanks’ Stock Analysis page.
